Mutations in the FLT3TKD+ gene are more severe and are mostly suggestive of a myeloid tumor. There are two main forms of FLT3 mutations, an internal tandem repeat mutation in the near-membrane structural domain (FLT3-ITD), and a point mutation (FLT3-TKD) or deletion in the structural domain of the tyrosine kinase. Only about 1/3 of these mutation types are FLT3-TKD. both mutations lead to aberrant activation of FLT3, which disrupts normal hematopoietic cell proliferation, differentiation, and apoptosis, leading to leukemogenesis and correlating with disease progression. FLT3 mutations are mainly seen in myeloid tumors, and it is the most common gene mutation in acute myeloid leukemia. For example, in myelodysplastic syndromes, mutations in FLT3-ITD+ and FLT3-TKD+ are relatively rare; whereas in advanced myelodysplastic syndromes, the chances of mutation increase dramatically.Mutations in the FLT3 gene can be used as a basis for prognostic stratification and targeted therapy. FLT3-TKD+ mutations are seen in approximately 7% of patients with first diagnosis of acute myeloid leukemia, and more frequently in patients with acute promyelocytic leukemia. Overall analysis of the prognostic significance of the presence of FLT3-TKD+ mutations in patients with acute myeloid leukemia was not significant.